# Genmab A/S

Type: Company (GMAB)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/genmab-as
Canonical HTML page: https://getfinancebrief.com/entity/genmab-as

## Recent coverage (2 stories)

### Genmab Faces Profit Squeeze as R&D for ADC Pipeline Weighs on 2026 Outlook
2026-02-19 08:27:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Full story: https://getfinancebrief.com/story/genmab-q4-2025-earnings-analysis-rd-spending

### Biotech Volatility and Earnings Pressures Define Mixed Market Session
2026-02-17 20:11:41 · Sentiment: Very Bullish · Impact: 7/10 · Sources: 9

The equity markets are navigating a complex landscape of 'sell-the-news' reactions and extreme biotech volatility following a series of clinical and financial updates. While Compass Pathways surged on positive trial results, Ocular Therapeutix and Genmab faced significant selling pressure despite reaching key milestones.
Full story: https://getfinancebrief.com/story/genmab-profit-drop-biotech-volatility-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.